Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 5/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809272 | 0.93 | MCL1 (0.35) | ALDH1A1KDM4EHPGDHSD17B10CCNC | |
| SCHEMBL26036900 | 0.93 | MCL1 (0.39) | ALDH1A1KDM4EHPGDHSD17B10PTGER4 | |
| SCHEMBL23809536 | 0.89 | ALDH1A1 (0.33) | ALDH1A1KDM4EHPGDHSD17B10GPR35 | |
| SCHEMBL23809113 | 0.89 | FABP3 (0.41) | ALDH1A1KDM4EHPGDHSD17B10CCNC | |
| SCHEMBL23809535 | 0.88 | KDM4E (0.36) | ALDH1A1KDM4EHPGDHSD17B10GPR35 | |
| SCHEMBL23809215 | 0.88 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDHSD17B10CCNC | |
| SCHEMBL23809529 | 0.85 | NTRK1 (0.38) | ALDH1A1KDM4EHPGDHSD17B10CCNC | |
| SCHEMBL23809370 | 0.85 | DHODH (0.39) | ALDH1A1KDM4EHPGDHSD17B10GPR35 | |
| SCHEMBL26581456 | 0.84 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10CCNC | |
| SCHEMBL23809128 | 0.84 | CCR2 (0.42) | ALDH1A1CCNCCDK8HASPINCASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.